450 related articles for article (PubMed ID: 30596222)
1. CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L; Zain J; Rosen ST; Querfeld C
Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
[TBL] [Abstract][Full Text] [Related]
2. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
Kempf W
Semin Diagn Pathol; 2017 Jan; 34(1):22-35. PubMed ID: 27993440
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous CD30(+) lymphoproliferative disorders.
Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
[TBL] [Abstract][Full Text] [Related]
4. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
[TBL] [Abstract][Full Text] [Related]
5. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
[TBL] [Abstract][Full Text] [Related]
6. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders.
Kempf W; Levi E; Kamarashev J; Kutzner H; Pfeifer W; Petrogiannis-Haliotis T; Burg G; Kadin ME
J Cutan Pathol; 2002 May; 29(5):295-300. PubMed ID: 12100631
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
Ferreira CR; Zhao S; Sanches JA; Miyashiro D; Cury-Martins J; Azevedo RS; Zerbini MCN; Natkunam Y; Gratzinger D
Diagn Pathol; 2019 Oct; 14(1):115. PubMed ID: 31640798
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
Kempf W; Kerl K; Mitteldorf C
Semin Cutan Med Surg; 2018 Mar; 37(1):24-29. PubMed ID: 29719017
[TBL] [Abstract][Full Text] [Related]
9. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
10. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
11. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 Expression in Primary Cutaneous CD30-Positive Lymphoproliferative Disorders and Transformed Mycosis Fungoides.
Mitteldorf C; Robson A; Tronnier M; Pfaltz MC; Kempf W
Dermatology; 2015; 231(2):164-70. PubMed ID: 26111483
[TBL] [Abstract][Full Text] [Related]
13. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME
Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362
[TBL] [Abstract][Full Text] [Related]
14. Mycosis Fungoides Associated With Lesions in the Spectrum of Primary Cutaneous CD30+ Lymphoproliferative Disorders: The Same Process or 3 Coexisting Lymphomas?
Cieza-Díaz DE; Prieto-Torres L; Rodríguez-Pinilla SM; Córdoba Mascuñano R; Manso Alonso R; Machan S; Piris Pinilla MÁ; Requena Caballero L
Am J Dermatopathol; 2019 Nov; 41(11):846-850. PubMed ID: 30946099
[TBL] [Abstract][Full Text] [Related]
15. Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin.
Drews R; Samel A; Kadin ME
Semin Cutan Med Surg; 2000 Jun; 19(2):109-17. PubMed ID: 10892712
[TBL] [Abstract][Full Text] [Related]
16. CD8-positive lymphomatoid papulosis (type D): Some lesions may lack CD30 expression and overlap histologically with mycosis fungoides.
Simo OC; Warren SJ; Mark L; Hoffmann K; Alomari AK
Int J Dermatol; 2019 Jul; 58(7):800-805. PubMed ID: 30520526
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
18. CD30+ neoplasms of the skin.
Duvic M
Curr Hematol Malig Rep; 2011 Dec; 6(4):245-50. PubMed ID: 21850406
[TBL] [Abstract][Full Text] [Related]
19. CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group.
Paulli M; Berti E; Rosso R; Boveri E; Kindl S; Klersy C; Lazzarino M; Borroni G; Menestrina F; Santucci M
J Clin Oncol; 1995 Jun; 13(6):1343-54. PubMed ID: 7751878
[TBL] [Abstract][Full Text] [Related]
20. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
Liu HL; Hoppe RT; Kohler S; Harvell JD; Reddy S; Kim YH
J Am Acad Dermatol; 2003 Dec; 49(6):1049-58. PubMed ID: 14639383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]